Skip to main content

Keyboard Shortcuts

Key Pair Function
Alt S Search Box
Alt T Top of Page
Alt H Home Page
Alt Index Button
Alt Next Button
Alt Prev Button
A4TE Logo

A4TE's Trans Health Project

Working for Transgender Equal Rights
Menu
  • Trans Health Insurance Tutorial
    • Choosing a Plan
    • Understanding Your Plan
    • Applying for Coverage
    • Understanding a Denial
    • Appealing a Denial
  • About Us
    • About A4TE's Trans Health Project
    • Privacy Policy
  • Contact Us
    • Contact A4TE
    • Contact A4TE's Trans Health Project
  • Resources
    • Legal Analysis
    • Medical Necessity Literature Reviews
    • Reporting Medical Provider Discrimination
    • Training Materials for Advocates
    • Provider Medical Necessity Letter Checklists
    • Health Insurance Medical Policies
    • Medical Organization Statements
    • State Health Insurance Laws and Guidance
    • Medicaid Regulations and Guidance
    • Gender Centers
    • Finding Trans Health Care Providers
    • State Employee Health Plans
    • Financial Aid for Transgender Surgeries
    • Gender Affirming Surgery Appeal Template
  • Tutorial del Seguro de Salud Trans
    • Cómo elegir un plan
    • Cómo entender su plan
    • Cómo solicitar cobertura
    • Cómo entender una denegación
    • Cómo apelar una denegación
Previous Page
Prev
Home
Home
Up
Up
Next Page
Next
  •  Home
  • Resources
  • Health Insurance Medical Policies
  • Current: Blue Cross Blue Shield of Northeastern New York - Gonadotropin-Releasing Hormone Agonists

Prev Index Gender Dysphoria/Reassignment [127 of 162] Next

Northeastern New York

Gonadotropin-Releasing Hormone Agonists


Policy: Gonadotropin-Releasing Hormone Agonists
Last Update: 2021-11-01
Next Update: 2022-03
Issued in: New York

Youth Services:

Coverage for Lupron Depot®/Lupron Depot Ped® is provided for treatment of the following conditions:

  • Gender dysphoria
  • The diagnosis of gender dysphoria and the referral for hormone therapy have been made by a mental health professional in accordance with the WPATH criteria AND o The patient must be followed by an endocrinologist AND
  • if used for suppression of puberty, therapy should not be started earlier than Tanner stage 2.

Back to top

Updated on Nov 23, 2021

Donate Now
Facebook Button Instagram Button
 Keyboard Shortcuts
 Privacy Policy
 A4TE Website

Copyright © 2024 Advocates For Trans Equality, Inc.  |  Tel: (202) 642-4542